Opko Health Says Intravitreal Dose of siRNA AMD Drug Reaches Target Tissues in Animals | GenomeWeb
Researchers from Opko Health last week published preclinical data showing that the company’s siRNA-based treatment for wet age-related macular degeneration, when injected intravitreally, is distributed throughout the eye, including to key retinal pigment epithelium cells.
The drug, called bevasiranib, is currently in phase III testing.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.